+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Diagnostics Market by Diagnostic Type, Indication, Components, End-Use - Global Forecast 2025-2030- Product Image
Cancer Diagnostics Market by Diagnostic Type, Indication, Components, End-Use - Global Forecast 2025-2030- Product Image
Sale

Cancer Diagnostics Market by Diagnostic Type, Indication, Components, End-Use - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011653
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Diagnostics Market grew from USD 29.95 billion in 2023 to USD 33.31 billion in 2024. It is expected to continue growing at a CAGR of 11.71%, reaching USD 65.06 billion by 2030.

Cancer diagnostics encompasses a range of technologies and procedures utilized to detect cancer at an early stage, aiding in prompt treatment and frequent monitoring of the disease's progression. This field holds crucial importance due to the growing prevalence of cancer globally, the increasing elderly population, and advancements in technology that have improved diagnostic accuracy. The application of cancer diagnostics spans various end-uses, such as hospitals, diagnostic centers, and research institutes, facilitating precise detection through techniques like imaging, biopsies, and molecular diagnostics. The market growth is significantly influenced by technological innovations such as next-generation sequencing, liquid biopsies, and artificial intelligence, which offer opportunities for early, non-invasive, and highly accurate cancer detection. However, the market faces challenges such as high costs of advanced diagnostics, regulatory hurdles, and disparate access to cutting-edge diagnostic solutions, especially in low-income countries. Despite these challenges, burgeoning opportunities lie in expanding cancer diagnostics to address undiagnosed cases in emerging markets, enhancing point-of-care diagnostics for quicker decision-making, and personalization of diagnostics for tailored therapy selections. Innovative areas include liquid biopsy development for real-time monitoring, AI-driven predictive analytics for risk assessment, and integration of digital health tools for streamlined diagnostics pathways. The sector is also likely to benefit from collaborative efforts between biotech firms and digital health companies to enhance data-driven diagnostic approaches. For businesses, seizing these opportunities involves focusing on affordable diagnostic solutions, investing in AI and machine learning for deeper analysis, and navigating regulatory landscapes effectively. While the competitive nature of this market is intense, success depends on balancing innovation with accessibility and cost-effectiveness, thereby enabling wider adoption and improved cancer management outcomes across different regions.

Understanding Market Dynamics in the Cancer Diagnostics Market

The Cancer Diagnostics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing burden of cancer among younger and geriatric population
    • Rising government initiatives and campaigns for cancer awareness
    • Favorable reimbursement framework for cancer diagnosis
  • Market Restraints
    • Associated high cost of cancer diagnostic equipment and lack of oncologists
  • Market Opportunities
    • Deployement of innovative tools for cancer screening, detection, and diagnostics
    • Integration of nanotechnology and nanomaterials in cancer diagnosis
  • Market Challenges
    • Inadequate and false results of cancer diagnostics

Exploring Porter’s Five Forces for the Cancer Diagnostics Market

Porter’s Five Forces framework further strengthens the insights of the Cancer Diagnostics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cancer Diagnostics Market

External macro-environmental factors deeply influence the performance of the Cancer Diagnostics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cancer Diagnostics Market

The Cancer Diagnostics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cancer Diagnostics Market

The Cancer Diagnostics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Cancer Diagnostics Market

The Cancer Diagnostics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., Becton, Dickinson & Company, Bio-Techne Corporation, bioMérieux SA, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Myriad Genetics, Natera, Inc., Perkin Elmer, Inc., Personal Genome Diagnostics Inc., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Diagnostic Type
    • Biopsy
    • Blood Chemistry Tests
      • Complete Blood Count (CBC)
      • Cytogenetic Analysis
      • Immunophenotyping
      • Liquid Biopsy
      • Sputum Cytology
      • Tumor Marker Tests
      • Urine Cytology
    • Imaging Tests
      • Bone Scan
      • CT-Scan
      • Magnetic Resonance Imaging (MRI)
      • Nuclear Scan
      • Positron Emission Tomography (PET) Scan
      • Ultrasound
      • X-Rays
  • Indication
    • Bladder Cancer
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Kidney Cancer
    • Liver Cancer
    • Lung Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Skin Cancer
  • Components
    • Consumables
    • Instruments
    • Software
  • End-Use
    • Diagnostic Laboratories
    • Hospitals
    • Research Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing burden of cancer among younger and geriatric population
5.1.1.2. Rising government initiatives and campaigns for cancer awareness
5.1.1.3. Favorable reimbursement framework for cancer diagnosis
5.1.2. Restraints
5.1.2.1. Associated high cost of cancer diagnostic equipment and lack of oncologists
5.1.3. Opportunities
5.1.3.1. Deployement of innovative tools for cancer screening, detection, and diagnostics
5.1.3.2. Integration of nanotechnology and nanomaterials in cancer diagnosis
5.1.4. Challenges
5.1.4.1. Inadequate and false results of cancer diagnostics
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cancer Diagnostics Market, by Diagnostic Type
6.1. Introduction
6.2. Biopsy
6.3. Blood Chemistry Tests
6.3.1. Complete Blood Count (CBC)
6.3.2. Cytogenetic Analysis
6.3.3. Immunophenotyping
6.3.4. Liquid Biopsy
6.3.5. Sputum Cytology
6.3.6. Tumor Marker Tests
6.3.7. Urine Cytology
6.4. Imaging Tests
6.4.1. Bone Scan
6.4.2. CT-Scan
6.4.3. Magnetic Resonance Imaging (MRI)
6.4.4. Nuclear Scan
6.4.5. Positron Emission Tomography (PET) Scan
6.4.6. Ultrasound
6.4.7. X-Rays
7. Cancer Diagnostics Market, by Indication
7.1. Introduction
7.2. Bladder Cancer
7.3. Blood Cancer
7.4. Breast Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Pancreatic Cancer
7.10. Prostate Cancer
7.11. Skin Cancer
8. Cancer Diagnostics Market, by Components
8.1. Introduction
8.2. Consumables
8.3. Instruments
8.4. Software
9. Cancer Diagnostics Market, by End-Use
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals
9.4. Research Centers
10. Americas Cancer Diagnostics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cancer Diagnostics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cancer Diagnostics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. New Funding to underpin development of Early Stage Cancer Platform Labmate Online
13.3.2. Owlstone Medical Enters Partnership with Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection
13.3.3. Cancer diagnostics company GenoME Diagnostics bags £1.4M funding
13.3.4. Ibex's Galen Prostate Becomes First Standalone AI-Powered Cancer Diagnostics Solution to Obtain CE Mark Under the IVDR
13.3.5. Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers
13.3.6. Microsoft Strikes Partnership with Paige To Advance Cancer Diagnostics and Treatment
13.3.7. Fujifilm India partners with Soorya Diagnostics LLP to launch CT Scan in Tirur
13.3.8. Biocare Medical Acquires Empire Genomics
13.3.9. Thermo Fisher ties up $2.6B deal for The Binding Site
13.3.10. Ibex Medical launches Galen 3.0 cancer diagnostics platform
13.3.11. Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
13.3.12. Karkinos Healthcare launches ‘Advanced Centre For Cancer Diagnostics and Research'
13.3.13. BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
13.3.14. Becton Dickinson Acquires Spanish Clinical Flow Cytometry Firm Cytognos
13.3.15. EarlySign Announces Strategic Agreement to Commercialize AI Solution for Early Detection of Cancer
13.3.16. Cancer Diagnostics, Inc. Acquires Anatech, Ltd.
13.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CANCER DIAGNOSTICS MARKET DYNAMICS
TABLE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPLETE BLOOD COUNT (CBC), BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CYTOGENETIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SPUTUM CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR MARKER TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY URINE CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BONE SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CT-SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY NUCLEAR SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY X-RAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 65. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 67. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 68. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 70. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 97. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 98. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 99. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 100. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 102. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 103. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 104. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 105. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 106. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 108. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 111. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 112. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 114. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 115. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 116. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 117. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 118. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 120. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 126. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 132. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 133. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 138. SINGAPORE CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 139. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 140. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 144. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 145. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 146. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 147. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 150. TAIWAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 151. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 152. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 153. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 154. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 156. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 157. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 158. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 159. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 160. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 162. VIETNAM CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 170. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 171. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 173. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 175. DENMARK CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 176. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 177. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 178. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 179. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 181. EGYPT CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 182. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 183. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 184. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 185. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 187. FINLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 188. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 189. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 190. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 191. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 193. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 194. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 195. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 196. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 197. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 199. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 200. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 201. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 202. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 206. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 207. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 208. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 209. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 211. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 212. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 213. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 214. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 215. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 221. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 223. NIGERIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 224. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 225. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 226. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 227. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 229. NORWAY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 230. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 231. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 232. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 233. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 235. POLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 236. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 237. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 238. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 239. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 241. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 260. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 261. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 262. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 263. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 264. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 265. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 272. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 273. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 274. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 275. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 277. SWITZERLAND CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 278. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 279. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 280. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 281. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 282. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 290. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CHEMISTRY TESTS, 2018-2030 (USD MILLION)
TABLE 292. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 294. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 296. CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 297. CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cancer Diagnostics market, which are profiled in this report, include:
  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • Becton, Dickinson & Company
  • Bio-Techne Corporation
  • bioMérieux SA
  • Castle Biosciences Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips N.V.
  • Myriad Genetics
  • Natera, Inc.
  • Perkin Elmer, Inc.
  • Personal Genome Diagnostics Inc.
  • Qiagen N.V.
  • Quest Diagnostics
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 33.31 Billion
Forecasted Market Value ( USD ) by 2030 $ 65.06 Billion
Compound Annual Growth Rate11.7%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Ovarian Cancer Diagnostics Market by Cancer Type, Diagnosis Type, End-User - Global Forecast 2025-2030 - Product Image

Ovarian Cancer Diagnostics Market by Cancer Type, Diagnosis Type, End-User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Breast Cancer Diagnostics Market by Technique, Cancer Type, Component, Diagnostic Type, End-User - Global Forecast 2025-2030 - Product Image

Breast Cancer Diagnostics Market by Technique, Cancer Type, Component, Diagnostic Type, End-User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Assay Kits And Reagents), By Test (Blood Test, Imaging Test), By End Use (Hospitals & Clinics), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Assay Kits And Reagents), By Test (Blood Test, Imaging Test), By End Use (Hospitals & Clinics), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report by Cancer Type (Melanoma, Non-Melanoma), Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy), End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report by Cancer Type (Melanoma, Non-Melanoma), Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy), End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 125 Pages
  • Global
From
Gastric Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Gastric Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.